Viking Therapeutics, Inc. (VKTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$36.6M
Cash & Equivalents
$114.0M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$3,297M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07104383 | VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | PHASE3 | Active Not Recruiting | 1,100 |
| NCT07104500 | VK2735 for Weight Management Phase 3 | PHASE3 | Active Not Recruiting | 4,500 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.